Cargando…

Lungenbeteiligung bei Tumorkrankheiten

The lungs are often involved in tumors and are affected in a wide variety of ways. Lung cancer comprises one of the most common cancer entities and has been characterized by a vast expansion of treatment approaches in recent years. Moreover, the lungs are a common metastatic site of multiple other c...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinmuth, N., Mavi, S.-C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782564/
http://dx.doi.org/10.1007/s11654-020-00280-x
_version_ 1783631932347645952
author Reinmuth, N.
Mavi, S.-C.
author_facet Reinmuth, N.
Mavi, S.-C.
author_sort Reinmuth, N.
collection PubMed
description The lungs are often involved in tumors and are affected in a wide variety of ways. Lung cancer comprises one of the most common cancer entities and has been characterized by a vast expansion of treatment approaches in recent years. Moreover, the lungs are a common metastatic site of multiple other cancer entities. Various treatment modalities, such as tyrosine kinase inhibitors, checkpoint inhibitors, chimeric antigen receptor cell therapy, and radiotherapy approaches can cause pulmonary side effects. Finally, many patients suffer from pulmonary comorbidities which may mutually impact the clinical course and prognosis of the cancer disease. As examples, various aspects, such as pulmonary veno-occlusive disease, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis are discussed.
format Online
Article
Text
id pubmed-7782564
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-77825642021-01-05 Lungenbeteiligung bei Tumorkrankheiten Reinmuth, N. Mavi, S.-C. best practice onkologie CME Topic The lungs are often involved in tumors and are affected in a wide variety of ways. Lung cancer comprises one of the most common cancer entities and has been characterized by a vast expansion of treatment approaches in recent years. Moreover, the lungs are a common metastatic site of multiple other cancer entities. Various treatment modalities, such as tyrosine kinase inhibitors, checkpoint inhibitors, chimeric antigen receptor cell therapy, and radiotherapy approaches can cause pulmonary side effects. Finally, many patients suffer from pulmonary comorbidities which may mutually impact the clinical course and prognosis of the cancer disease. As examples, various aspects, such as pulmonary veno-occlusive disease, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis are discussed. Springer Medizin 2021-01-05 2021 /pmc/articles/PMC7782564/ http://dx.doi.org/10.1007/s11654-020-00280-x Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle CME Topic
Reinmuth, N.
Mavi, S.-C.
Lungenbeteiligung bei Tumorkrankheiten
title Lungenbeteiligung bei Tumorkrankheiten
title_full Lungenbeteiligung bei Tumorkrankheiten
title_fullStr Lungenbeteiligung bei Tumorkrankheiten
title_full_unstemmed Lungenbeteiligung bei Tumorkrankheiten
title_short Lungenbeteiligung bei Tumorkrankheiten
title_sort lungenbeteiligung bei tumorkrankheiten
topic CME Topic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7782564/
http://dx.doi.org/10.1007/s11654-020-00280-x
work_keys_str_mv AT reinmuthn lungenbeteiligungbeitumorkrankheiten
AT mavisc lungenbeteiligungbeitumorkrankheiten